Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cranial Nerve Disorder Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT07348276
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional

RAD 1501: A Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery

NCT02708810
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Unframed Virtual Cone, 80 Gy Radiation
Device · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

NCT02003144
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • Oceanside, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach

NCT02309099
View directory record Official record
Conditions
Unilateral Acoustic Neuroma, Meniere's Disease
Interventions
Cochlear Implant
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Functional Outcomes in Patients With Unilateral Vocal Cord Paralysis: Assessment of Adaptation Using Functional Magnetic Resonance Imaging

NCT00597844
View directory record Official record
Conditions
Intrathoracic Malignancies, Unilateral Vocal Cord Paralysis
Interventions
voice evaluation and fMRI, undergo voice evaluation and fMRI prior
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jul 22, 2026, 2:22 AM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Recovery of Visual Acuity in People With Vestibular Deficits

NCT00411216
View directory record Official record
Conditions
Vestibular Neuronitis, Vestibular Neuronitis, Bilateral, Vestibular Schwannoma
Interventions
Control exercises, gaze stabilization exercises
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Jul 22, 2026, 2:22 AM EDT
Not listed Not applicable Interventional

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

NCT01586767
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Squamous Cell Carcinoma, Sinonasal Carcinoma, Sinonasal Undifferentiated Carcinoma, Mucoepidermoid Carcinoma, Schneiderian Carcinoma, Myoepithelial Carcinoma, Esthesioneuroblastoma, Melanoma
Interventions
Proton radiation therapy, Intensity-modulated radiotherapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 2:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolic Syndrome in Childhood Cancer Survivors

NCT00920738
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Metabolic Syndrome, Sarcoma
Interventions
metabolic assessment, questionnaire administration
Other
Lead sponsor
University of Minnesota
Other
Eligibility
9 Years to 18 Years
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jul 22, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 22, 2026, 2:22 AM EDT
Completed No phase listed Observational

Pediatric NMOSD Observational Study

NCT03766347
View directory record Official record
Conditions
Neuromyelitis Optica, NMO Spectrum Disorder
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Jul 22, 2026, 2:22 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 22, 2026, 2:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

NCT06517888
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
AAVAnc80-antiVEGF via Akouos Delivery Device
Combination Product
Lead sponsor
Akouos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

NCT02391961
View directory record Official record
Conditions
Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 2Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Davunetide, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
41 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Jul 22, 2026, 2:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

MS-ResearchBiomarkerS

NCT05204459
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2041
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jul 22, 2026, 2:22 AM EDT
Completed No phase listed Observational

Natural History Study of FDXR Mutation-related Mitochondriopathy

NCT04580979
View directory record Official record
Conditions
Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
Interventions
Mutation analysis
Genetic
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
0 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

NCT00973739
View directory record Official record
Conditions
Neurofibromatosis 2, Vestibular Schwannoma
Interventions
Lapatinib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
4 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

NCT00019331
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 22, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Randomized Trial of Treatments for Convergence Insufficiency

NCT00347945
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Pencil Push-ups, Office-based Vision Therapy, Placebo Office-based Vision Therapy
Procedure
Lead sponsor
Pennsylvania College of Optometry
Industry
Eligibility
9 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
7
States / cities
Fullerton, California • New York, New York • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Jul 22, 2026, 2:22 AM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 22, 2026, 2:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Neural Disorders

NCT02761707
View directory record Official record
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Jul 22, 2026, 2:22 AM EDT